Localization and Maintenance of Engrafted Mesenchymal Stem Cells Administered via Renal Artery in Kidneys with Ischemia-Reperfusion Injury

Mesenchymal stem cells (MSCs) are a potential therapeutic tool for preventing the progression of acute kidney injury (AKI) to chronic disease (CKD). Herein, we investigated localization and maintenance engrafted human bone marrow-derived MSCs in rats subjected renal ischemia-reperfusion (IRI) compared effectiveness two intravascular injection routes via artery or inferior vena cava. Renal was more effective than intravenous at reducing IRI-induced fibrosis. Additionally, injected through persisted injured kidneys over 21 days, whereas cava survived less 7 days. This difference may be attributed antifibrotic effects MSCs. Interestingly, were localized primarily glomeruli until day 3 post-IRI, they decreased number thereafter. In contrast, tubular walls, interstitium increased gradually post-IRI. change related areas damage caused by IRI because ischemia-induced AKI leads cell damage. Taken together, these findings suggest useful CKD.